Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

Jones, Simon Arnett ORCID: https://orcid.org/0000-0001-7297-9711, Scheller, Jürgen and Rose-John, Stefan 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation 121 (9) , pp. 3375-3383. 10.1172/JCI57158

Preview

PDF - Published Version Download (485kB) | Preview

Abstract

The successful treatment of certain autoimmune conditions with the humanized anti–IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	Q Science > QR Microbiology > QR180 Immunology R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology
Additional Information:	Science in Medicine. Pdf uploaded in accordance with publisher's policy at http://www.sherpa.ac.uk/romeo/issn/0021-9738/ (accessed 24/02/2014)
Publisher:	American Society for Clinical Investigation
ISSN:	0021-9738
Date of First Compliant Deposit:	30 March 2016
Last Modified:	02 May 2023 16:52
URI:	https://orca.cardiff.ac.uk/id/eprint/28640

Citation Data

Cited 521 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item